Authors: ChinFan Chen MingYii Huang ChihJen Huang ChanHan Wu YungSung Yeh HsiangLin Tsai ChengJen Ma ChienYu Lu ShunJen Chang MingJenn Chen JawYuan Wang
Publish Date: 2012/01/19
Volume: 27, Issue: 6, Pages: 727-736
Abstract
Seventyfour patients were retrospectively analyzed Twentyseven patients were treated with 5FU 350 mg/m2 IV bolus and leucovorin 20 mg/m2 IV bolus for 5 days/week during week 1 and 5 of RT Fortyseven patients were treated with capecitabine 850 mg/m2 twice daily for 5 days/week Both groups received the same RT course 45–504 Gy/25 fractions 5 days/week for 5 weeks Patients underwent surgery in 6 weeks after completion of the chemoradiotherapy Data of the observational study were collectedGrade 3 or 4 toxicities occurred in 407 5FU and 191 capecitabine of the patients P = 0044 Six patients in the 5FU group 222 and six patients in the capecitabine group 14 achieved complete response Primary tumor T downstaging were achieved in 519 5FU and 698 capecitabine of the patients The pathological ypT02 stage was 407 5FU and 674 capecitabine P = 0028In consideration of the better ypT02 downstaging rate less severe toxicities and no need for indwelling intravenous device on oral capecitabine regimen the administration of oral capecitabine with RT may be a more favorable option in the neoadjuvant treatment for LARCThis study was supported by grants from the Excellence for Cancer Research Center Grant through the funding by Department of Health Executive Yuan Taiwan Republic of China DOH101TDC111002 and the Kaohsiung Medical University Hospital KMUH988I04
Keywords: